Literature DB >> 19436568

Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based study.

Martin Sénécal1, Marc Brisson, Marc H Lebel, John Yaremko, Richard Wong, Lee Ann Gallant, Hartley A Garfield, Darryl J Ableman, Richard L Ward, John S Sampalis, James A Mansi.   

Abstract

BACKGROUND: Current assessments of the burden of rotavirus (RV)-related gastroenteritis are needed to evaluate the potential benefits of RV immunization interventions. The objective of the present study was to characterize the burden of RV gastroenteritis among children presenting in outpatient settings with gastroenteritis.
METHODS: Between January and June 2005, 395 children younger than three years of age presenting with gastroenteritis symptoms (at least three watery or looser-than-normal stools, or forceful vomiting within the previous 24 h period) were recruited from 59 Canadian clinics and followed for two weeks. Stool specimens were tested for the RV antigen. Gastroenteritis-related symptoms, health care utilization, parental work loss and other cases of gastroenteritis in the household were assessed by questionnaires and daily symptom cards that were completed by caregivers.
RESULTS: Of 336 conclusive test results, 55.4% were RV positive (RV+). In addition to diarrhea, 67.2% and 89.3% of RV+ children experienced fever or vomiting, respectively. Compared with RV-negative (RV-) children, RV+ children were more likely to experience the three symptoms concurrently (57.0% versus 26.7%; P<0.001), to be hospitalized (12.9% versus 3.9%; P=0.008) and to induce parental work loss (53.8% versus 37.3%; P=0.003). The median duration of gastroenteritis was eight days for RV+ children (nine days for RV- children). Additional cases of gastroenteritis were present in 46.8% of households in the RV+ group (51.3% of households in the RV- group).
CONCLUSIONS: RV gastroenteritis cases were more severe than other gastroenteritis cases, were hospitalized more often and were associated with considerably more work loss.

Entities:  

Keywords:  Burden of illness; Gastroenteritis; Health care resource utilization; Rotavirus; Work loss

Year:  2008        PMID: 19436568      PMCID: PMC2663469          DOI: 10.1155/2008/451540

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  47 in total

1.  Rotavirus in Ireland: national estimates of disease burden, 1997 to 1998.

Authors:  M Lynch; F O'Halloran; D Whyte; S Fanning; B Cryan; R I Glass
Journal:  Pediatr Infect Dis J       Date:  2001-07       Impact factor: 2.129

2.  Hospital-based study of the economic burden associated with rotavirus diarrhea in Hong Kong.

Authors:  E Anthony S Nelson; John S Tam; Ly-Mee Yu; Ying-Chu Ng; Joseph S Bresee; Kin-Hung Poon; Chi-Hang Ng; Kin-Sing Ip; T Christopher Mast; Paul K-S Chan; Umesh D Parashar; Tai-Fai Fok; Roger I Glass
Journal:  J Infect Dis       Date:  2005-09-01       Impact factor: 5.226

3.  Hospitalization for community-acquired, rotavirus-associated diarrhea: a prospective, longitudinal, population-based study during the seasonal outbreak. The Greater Toronto Area/Peel Region PRESI Study Group. Pediatric Rotavirus Epidemiology Study for Immunization.

Authors:  E L Ford-Jones; E Wang; M Petric; P Corey; R Moineddin; M Fearon
Journal:  Arch Pediatr Adolesc Med       Date:  2000-06

4.  Incidence of hospitalizations due to rotavirus gastroenteritis in Denmark.

Authors:  T K Fischer
Journal:  Acta Paediatr       Date:  2001-09       Impact factor: 2.299

Review 5.  Rotavirus disease and its prevention in infants and children.

Authors:  M A Raebel; B S Ou
Journal:  Pharmacotherapy       Date:  1999-11       Impact factor: 4.705

6.  Rotavirus gastroenteritis in Italian children: can severity of symptoms be related to the infecting virus?

Authors:  A Cascio; E Vizzi; C Alaimo; S Arista
Journal:  Clin Infect Dis       Date:  2001-03-23       Impact factor: 9.079

7.  Economic analysis of rotavirus-associated diarrhea in the metropolitan Toronto and Peel regions of Ontario.

Authors:  P Jacobs; Lg Shane; K Fassbender; El Wang; R Moineddin; El Ford-Jones
Journal:  Can J Infect Dis       Date:  2002-05

8.  Vaccines for rotavirus gastroenteritis universally needed for infants.

Authors:  H Fred Clark; Paul A Offit
Journal:  Pediatr Ann       Date:  2004-08       Impact factor: 1.132

9.  Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000.

Authors:  Hwa-Gan H Chang; Roger I Glass; Perry F Smith; Helen G Cicirello; Robert C Holman; Dale L Morse
Journal:  Pediatr Infect Dis J       Date:  2003-09       Impact factor: 2.129

Review 10.  A review of vaccine research and development: human enteric infections.

Authors:  Marc P Girard; Duncan Steele; Claire-Lise Chaignat; Marie Paule Kieny
Journal:  Vaccine       Date:  2005-10-21       Impact factor: 3.641

View more
  11 in total

1.  Literature Review on Rotavirus: Disease and Vaccine Characteristics: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  E L Ford-Jones; S Calvin
Journal:  Can Commun Dis Rep       Date:  2010-11-30

2.  Updated Statement on the use of Rotavirus Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-07-16

Review 3.  Rotavirus infection.

Authors:  Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes
Journal:  Nat Rev Dis Primers       Date:  2017-11-09       Impact factor: 52.329

4.  Group A rotaviruses in children with gastroenteritis in a Canadian pediatric hospital: The prevaccine era.

Authors:  Estelle Chetrit; Yvan L'homme; Jagdip Singh Sohal; Caroline Quach
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

5.  The impact of childhood acute rotavirus gastroenteritis on the parents' quality of life: prospective observational study in European primary care medical practices.

Authors:  Javier Diez Domingo; Marian Patrzalek; Luigi Cantarutti; Benoit Arnould; Juliette Meunier; Montse Soriano-Gabarro; Nadia Meyer; Jean-Yves Pirçon; Katsiaryna Holl
Journal:  BMC Pediatr       Date:  2012-05-31       Impact factor: 2.125

6.  Implementation of a universal rotavirus vaccination program: comparison of two delivery systems.

Authors:  Mitchell Zelman; Carolyn Sanford; Anne Neatby; Beth A Halperin; Donna MacDougall; Corinne Rowswell; Joanne M Langley; Scott A Halperin
Journal:  BMC Public Health       Date:  2014-09-02       Impact factor: 3.295

7.  Multicenter prospective study on the burden of rotavirus gastroenteritis in children less than 3 years of age in Spain.

Authors:  J Arístegui; J Ferrer; I Salamanca; E Garrote; A Partidas; M San-Martin; B San-Jose
Journal:  BMC Infect Dis       Date:  2016-10-10       Impact factor: 3.090

8.  Evaluating a knowledge translation tool for parents about pediatric acute gastroenteritis: a pilot randomized trial.

Authors:  Lauren Albrecht; Shannon D Scott; Lisa Hartling
Journal:  Pilot Feasibility Stud       Date:  2018-08-02

9.  Impact of emergency department probiotic treatment of pediatric gastroenteritis: study protocol for the PROGUT (Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment) randomized controlled trial.

Authors:  Stephen B Freedman; Sarah Williamson-Urquhart; Suzanne Schuh; Philip M Sherman; Ken J Farion; Serge Gouin; Andrew R Willan; Ron Goeree; David W Johnson; Karen Black; David Schnadower; Marc H Gorelick
Journal:  Trials       Date:  2014-05-14       Impact factor: 2.279

10.  Health-related quality of life of the parents of children hospitalized due to acute rotavirus infection: a cross-sectional study in Latvia.

Authors:  Gunta Laizane; Anda Kivite; Inese Stars; Marita Cikovska; Ilze Grope; Dace Gardovska
Journal:  BMC Pediatr       Date:  2018-03-15       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.